Enzon Pharmaceuticals, Inc. Stock Other OTC
Equities
ENZN
US2939041081
Biotechnology & Medical Research
Sales 2022 | 26K 35.7K | Sales 2023 | - | Capitalization | 6.94M 9.53M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | 1M 1.37M | EV / Sales 2022 | -1,103 x |
Net cash position 2022 | 46.98M 64.52M | Net cash position 2023 | 47.01M 64.56M | EV / Sales 2023 | - |
P/E ratio 2022 |
-12.5
x | P/E ratio 2023 |
70.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.16% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 80 | 13-12-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randolph Read
CHM | Chairman | 71 | 20-08-03 |
Director/Board Member | 67 | 22-06-30 | |
Jordan Bleznick
BRD | Director/Board Member | 68 | 20-08-03 |
1st Jan change | Capi. | |
---|---|---|
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |